

Parameters	Tsoi <i>et al.</i> (2010) <sup>135</sup>	OHTA (2011) <sup>134,136</sup>
Country	Canada	
Perspective (costs)	Health care	
Comparators (NPI, Adjuvant! Online)	Adjuvant! Online vs. Adjuvant! Online + RS	
Starting age in the model	50 years	
Population	ER+, LN-, HER2- early breast cancer	
Model structure (type, health states)	Markov model with five health states (risk reclassification, chemotherapy, recurrence free, distant recurrence and death)	
Definition of relapse	Distant metastases only	Distant metastases only
Time horizon	Lifetime	
Endocrine therapy regime	5 years of tamoxifen	
Chemotherapy regime	Four cycles of AC – in the base case	TC or FEC-D
Benefit of chemotherapy	30% relative risk reduction	Low: no benefit; intermediate: 39% reduction; high: 74% reduction
Adverse events	Minor (60%), major (5%)	
Definition of high risk	Intermediate was grouped with high risk for RS For Adjuvant! Online, arbitrary decision so that same proportion of low cases between Adjuvant! Online and RS	Adjuvant! Online: low risk: mortality <9%; intermediate risk: 9% ≤ mortality < 17%; high risk: mortality ≥ 17%
Quality of life	Different valuation methods (VAS – SG) Adjuvant! Online/RS: 0.94 Major toxicity: 0.8 Minor toxicity: 0.9 No toxicity: 0.94 Recurrence free after chemotherapy: 0.98 Distant recurrence: 0.75	

VAS–SG, visual analogue scale – standard gamble.

Parameters	Tsoi <i>et al.</i> (2010) <sup>135</sup>	OHTA (2011) <sup>134,136</sup>
Costs and resources used	2008 Canadian dollars; inflation rate assumed to be 5% per year Oncotype: C\$4,404 Chemotherapy per cycle: C\$768.3 Major non-fatal toxicity: C\$2459 Major fatal toxicity: C\$28,385 Recurrence free (yearly): C\$444 Tamoxifen (5 years): C\$678 Distant metastases (21 months): C\$35,023 Terminal care (last 3 months): C\$21,367	The majority of costs have been adapted from Tsoi <i>et al.</i> <sup>135</sup> to reflect 2010 prices. The costs of OncotypeDX (C\$4191) and chemotherapy have been updated
Discounting	5% for both costs and benefits	